COMPOUNDING, WHICH INHIBITES ACTIVITY OF BTK AND/OR JAK3 KINASES Russian patent published in 2018 - IPC C07D487/04 C07D491/48 C07D495/04 A61K31/53 A61K31/519 A61K31/5377 A61P37/02 A61P29/00 A61P7/02 A61P35/00 A61P19/02 A61P11/00 A61P17/06 A61P1/00 

FIELD: chemistry.

SUBSTANCE: present invention refers to the new compound of formula I, or to the stereoisomer thereof, or to the pharmaceutically acceptable salt, which has the properties of Bruton tyrosine kinase (BTK) activity inhibitor and/or Janus kinase 3 (JAK3). In the formula I (I) R is C_3-8cycloalkyl substituted with the -NR²W group; 4-10 membered saturated N-heterocyclic group, which contains only one nitrogen atom in its ring and this nitrogen atom is replaced by W; or C_1-4alkyl substituted with the 4-10 membered saturated N-heterocyclic group, which contains only one nitrogen atom in its ring and this nitrogen atom is replaced by W; W denotes or ; V denotes C or N; X denotes NR⁴ or O; Y denotes CH, S or O; Z is CH, S, O or NR⁵; R¹ is phenyl or 5-9 membered heteroaryl, which contains 1-2 heteroatoms that are selected from nitrogen, oxygen and sulfur, optionally substituted by one or two R⁶; R² is hydrogen or C_1-8alkyl; R^3a, R^3b and R^3c denote hydrogen; R⁴ is hydrogen or C_1-8alkyl; R⁵ is hydrogen or C_1-8alkyl; each R⁶ is independently selected from the group, which consists of halogen, heterocyclyl, C_1-8alkyl, C₁-C₈cycloalkyl, C_1-8haloalkyl, heterocyclyl-C_1-8alkyl, hydroxy-C_1-8alkyl, C_1-8alkyloxy-C_1-8alkyl, amino-C_1-8alkyl, C_1-8alkylamino-C_1-8alkyl, di(C_1-8alkyl) amino-C_1-8alkyl, C_1-8alkyloxy, heterocyclyloxy, heterocyclyl-C_1-8alkyloxy, hydroxy-C_1-8alkyloxy, C_1-8alkyloxy-C_1-8alkyloxy, C_1-8alkylamino, di(C_1-8alkyl) amino, C₃-C₈cycloalkylamino, heterocyclylamino, C_1-8alkylamino-C_1-8alkylamino, di(C_1-8alkyl) amino-C_1-8alkylamino, C_1-8alkylcarbonyl, heterocyclylcarbonyl, C_1-8alkylaminoacyl, di(C_1-8alkyl) aminoacyl and heterocyclylaminoacyl, where in the given C_1-8alkylaminoacyl, di(C_1-8alkyl) aminoacyl and heterocyclylaminoacyl acyl denote the group -C(=O)-; and heterocyclyl as an independent group or as part of other group(s) is the saturated 6-membered heterocyclic group, which contains one or two heteroatoms that are selected from the group, which consists of N and O; optionally, each heterocyclyl is independently substituted with one or two substituents that are selected from the group, which consists of C_1-8alkyl, hydroxy, C_1-8alkyloxy and C_1-8alkylcarbonyl.

EFFECT: compound can be used during the treatment of diseases such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis, the cancer that is selected from the group, which consists of B-cell chronic lymphocytic leukemia, acute lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, diffuse large-cell B-cell lymphoma, lymphoma of mantle cells and small-cell lymphocytic lymphoma.

24 cl, 3 dwg, 11 tbl, 145 ex